Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension
Med Page Today
MARCH 27, 2024
(MedPage Today) -- The FDA approved sotatercept (Winrevair) for treating pulmonary arterial hypertension (PAH) in adults, Merck announced on Tuesday. A novel activin signaling inhibitor, sotatercept is indicated to increase exercise capacity.
Let's personalize your content